On Air Now

Listen

Listen Live Now » 101.1 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
48° Feels Like: 43°
Wind: SSW 10 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Showers Late 46°

Tomorrow

Showers 65°

Mon Night

Thundershowers 50°

Alerts

Bayer seeks U.S. FDA approval for radium-223

FRANKFURT (Reuters) - German drugmaker Bayer said on Friday it requested approval from U.S. regulators for an experimental prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.

Radium-223 dichloride, which Bayer used to call Alpharadin, is designed to target bone metastases from prostate cancer that cannot be treated by standard hormone therapy.

On Wednesday, Bayer said it was requesting EU approval for the drug.

Bayer said last year that Radium-223 dichloride could become a "blockbuster" product with annual sales of least 1 billion euros.

The drug has some properties of calcium, which makes it cling to cancerous bone cells and then destroy them via alpha rays, which is more targeted that the shotgun approach of conventional radiotherapy.

(Reporting by Jonathan Gould)

Comments